← Back to patent-cliff list
Romaciclib
Tier C — Watch / tradeRomaciclib
Ryvu Therapeutics Sa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CDK8, CDK19
Indications (approved)：Solid tumour, Myelodysplastic syndrome, Acute myeloid leukaemia, Myelofibrosis
Regional status
US
Discontinued
2019-09-04
EU
Phase II
2021-08-13
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Romaciclib?
Approved indications include: Solid tumour, Myelodysplastic syndrome, Acute myeloid leukaemia, Myelofibrosis.
When does the Romaciclib patent expire?
No public expiry year is available for Romaciclib yet; this page updates once verified.
How do I get a quote for Romaciclib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06